Chromatographic method and system for purifying a botulinum toxin
Chromatographic processes and systems for purifying a botulinum toxin from an APF fermentation medium.
1. A substantially animal protein free (“APF”) process for purifying a biologically active botulinum toxin, the process comprising the steps of:
(a) obtaining a fermentation medium which comprises a biologically active botulinum toxin, wherein the fermentation medium comprising a biologically active botulinum toxin results from a substantially, essentially or entirely APF fermentation process;
(b) filtering the fermentation medium;
(c) precipitating the botulinum toxin from the filtered fermentation medium to thereby obtain a precipitate;
(d) extracting the botulinum toxin from the precipitate;
(e) contacting a first chromatography column with the extracted botulinum toxin, wherein the first chromatography column is either a hydrophobic interaction chromatography column or an ion exchange chromatography column;
(f) eluting the botulinum toxin from the first chromatography column;
(g) contacting a second chromatography column with the botulinum toxin containing eluent from the first chromatography column, wherein the second chromatography column is either a hydrophobic interaction chromatography column or an ion exchange chromatography column;
(h) eluting the botulinum toxin from the second chromatography column;
(i) contacting a third chromatography column with the botulinum toxin containing eluent from the second chromatography column wherein the third chromatography column is either a mixed mode chromatography column or an ion exchange chromatography column, and;
(j) eluting the botulinum toxin from the third chromatography column, thereby obtaining the purified biologically active botulinum toxin, wherein the first chromatography column, the second chromatography column, and the third chromatography column are different chromatography columns.
2. The process for purifying a botulinum toxin of claim 1 , wherein the botulinum toxin fermentation medium results from a substantially APF fermentation process.
3. The process for purifying a botulinum toxin of claim 1 , wherein the botulinum toxin fermentation medium results from an essentially APF fermentation process.
4. The process for purifying a botulinum toxin of claim 1 , wherein the botulinum toxin fermentation medium results from an entirely APF fermentation process.
5. The process for purifying a botulinum toxin of claim 1 , wherein the purified botulinum toxin obtained has a potency of up to about 100 million mouse LD 50 units per milligram of the purified botulinum toxin.
6. The process for purifying a botulinum toxin of claim 1 , wherein the purified botulinum toxin obtained has as little as about 30 ng of residual nucleic acids per mg of the purified botulinum toxin.
7. The process for purifying a botulinum toxin of claim 1 , wherein the purified botulinum toxin obtained has a ratio of absorbance at 260 nm to it's absorbance at 278 nm (A 260 /A 278 ) as low as about 0.50.
8. An APF process for purifying a biologically active botulinum toxin, the process comprising the steps of:
(a) obtaining an APF fermentation medium which comprises a biologically active botulinum toxin, wherein the fermentation medium comprising a biologically active botulinum toxin results from an APF fermentation process;
(b) filtering the APF fermentation medium;
(c) precipitating the botulinum toxin from the filtered APF fermentation medium to thereby obtain a precipitate;
(d) extracting the botulinum toxin from the precipitate;
(e) contacting a first chromatography column with the extracted botulinum toxin, wherein the first chromatography column is either a hydrophobic interaction chromatography column or an ion exchange chromatography column;
(f) eluting the botulinum toxin from the first chromatography column;
(g) contacting a second chromatography column with the botulinum toxin containing eluent from the first chromatography column, wherein the second chromatography column is either a hydrophobic interaction chromatography column or an ion exchange chromatography column;
(h) eluting the botulinum toxin from the second chromatography column;
(i) contacting a third chromatography column with the botulinum toxin containing eluent from the second chromatography column wherein the third chromatography column is either a mixed mode chromatography column or an ion exchange chromatography column, and;
(j) eluting the botulinum toxin from the third chromatography column, thereby obtaining the purified biologically active botulinum toxin, wherein the first chromatography column, the second chromatography column, and the third chromatography column are different chromatography columns.
9. The process of claim 8 , wherein the purified botulinum toxin obtained has a potency of up to about 100 million mouse LD 50 units per milligram of the purified botulinum toxin.
10. The process of claim 8 , wherein the purified botulinum toxin obtained has as little as about 30 ng of residual nucleic acids per mg of the purified botulinum toxin.
11. The process of claim 8 , wherein the purified botulinum toxin obtained has a ratio of absorbance at 260 nm to absorbance at 278 nm (A 260 /A 278 ) as low as about 0.50.
12. An essentially animal protein free (“APP”) process for purifying a biologically active botulinum toxin, the process comprising the steps of:
(a) obtaining a fermentation medium which comprises a biologically active botulinum toxin, wherein the fermentation medium comprising a biologically active botulinum toxin results from an essentially or entirely APF fermentation process;
(b) filtering the fermentation medium;
(c) precipitating the botulinum toxin from the filtered fermentation medium to thereby obtain a precipitate;
(d) extracting the botulinum toxin from the precipitate;
(e) contacting a first chromatography column with the extracted botulinum toxin, wherein the first chromatography column is either a hydrophobic interaction chromatography column or an ion exchange chromatography column;
(f) eluting the botulinum toxin from the first chromatography column;
(g) contacting a second chromatography column with the botulinum toxin containing eluent from the first chromatography column, wherein the second chromatography column is either a hydrophobic interaction chromatography column or an ion exchange chromatography column;
(h) eluting the botulinum toxin from the second chromatography column;
(i) contacting a third chromatography column with the botulinum toxin containing eluent from the second chromatography column wherein the third chromatography column is either a mixed mode chromatography column or an ion exchange chromatography column, and;
(j) eluting the botulinum toxin from the third chromatography column, thereby obtaining the purified biologically active botulinum toxin, wherein the first chromatography column, the second chromatography column, and the third chromatography column are different chromatography columns.
13. The process for purifying a botulinum toxin of claim 12 , wherein the purified botulinum toxin obtained has a potency of up to about 100 million mouse LD 50 units per milligram of the purified botulinum toxin.
14. The process for purifying a botulinum toxin of claim 12 , wherein the purified botulinum toxin obtained has as little as about 30 ng of residual nucleic acids per mg of the purified botulinum toxin.
15. The process for purifying a botulinum toxin of claim 12 , wherein the purified botulinum toxin obtained has a ratio of absorbance at 260 nm to it's absorbance at 278 nm (A 260 /A 278 ) as low as about 0.50.
16. The process for purifying a botulinum toxin of claim 12 , wherein the botulinum toxin fermentation medium results from an essentially APF fermentation process.
17. The process for purifying a botulinum toxin of claim 12 , wherein the botulinum toxin fermentation medium results from an entirely APF fermentation process.